Descripción de la empresa
Sangamo Therapeutics, Inc. operates as a clinical-stage genomic medicine company dedicated to translating scientific discoveries into medicines designed to transform the lives of patients and families suffering from serious diseases within the United States. The company functions within the Healthcare sector and specifically within the Biotechnology industry, positioning it as an entity focused on the development of novel therapeutic products rather than the commercialization of established pharmaceuticals. As of the latest available data, the company holds a market capitalization of $106.10M and reports an annual revenue (TTM) of $39.55M, while the specific count of employees is not disclosed in the provided records. These valuation and revenue figures indicate that Sangamo remains a small-cap biotechnology entity with limited scale, reflecting the typical characteristics of firms in the early clinical stages that are still investing heavily in research and development before achieving commercial profitability.
Salud financiera
Sangamo Therapeutics reported a revenue of $39.55M over the trailing twelve months, yet the company recorded a net income loss of $-122,932,000 and an EBITDA of $-104,043,000, revealing a significant gap between top-line sales and bottom-line profitability that underscores a heavy cost structure driven by clinical trial expenses and operational overhead. The company's free cash flow stands at $-56,760,500, indicating a continuous burn of cash reserves which limits immediate financial flexibility and necessitates reliance on external capital sources to fund ongoing operations. The gross margin is reported at -184.9%, the operating margin at -175.5%, and the profit margin at 0.0%, figures that collectively demonstrate that current revenue generation is insufficient to cover the direct costs of sales or operational expenses, resulting in a loss on nearly every dollar of sales. Regarding liquidity and leverage, the company holds $20.95M in cash against $26.80M in debt, while the debt-to-equity ratio is listed as N/A due to the negative equity position. This balance sheet configuration suggests a leveraged stance typical for biotech firms where assets are often intangible and cash reserves are depleted by development costs. The current ratio is 0.84, a metric below 1.0 that indicates the company possesses fewer current assets than current liabilities, signaling potential short-term liquidity constraints. Furthermore, the Return on Equity is -2891.8% and the Return on Assets is -83.7%, metrics that reveal the company is currently destroying value per unit of capital employed rather than generating returns for shareholders or efficiently utilizing its asset base.
Evaluación de valoración
The valuation metrics for Sangamo Therapeutics present a complex picture, with a trailing P/E ratio of N/A due to the lack of positive earnings, contrasted by a forward P/E of 9.60 which implies market expectations of future profitability once clinical milestones are achieved. The price-to-book ratio is -6.25, a negative figure that indicates the market values the company at a significant discount to its book value, often seen in firms with substantial intangible assets or potential liabilities not fully reflected on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 2.68 and an EV/EBITDA of -1.08 suggest that the company is being valued based on its revenue generation potential and enterprise value relative to earnings power, rather than traditional earnings multiples. In terms of trading range, the 52-week high is $0.84 and the 52-week low is $0.21, meaning the current price sits within a wide volatility band that has expanded significantly over the past year. The stock exhibits a beta of 1.50, which indicates that the share price is expected to be 50% more volatile than the broader market, reflecting the high risk profile associated with clinical-stage biotechnology investments.
Growth & Income
Sangamo Therapeutics demonstrated a revenue growth of 88.4% year-over-year, whereas the earnings growth is listed as N/A due to the absence of positive net income, implying that top-line expansion is occurring without a corresponding improvement in profitability at this stage of development. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that the firm retains all available cash to reinvest into research, development, and clinical trials rather than distributing income to shareholders. This strategy of reinvestment is characteristic of clinical-stage genomic medicine companies that prioritize advancing their product candidates, such as ST-920, over providing immediate income returns to investors. Overall, the company's profile is defined by rapid revenue expansion and total reinvestment of earnings, presenting a high-risk, high-potential reward scenario typical of the biotechnology sector where future value realization depends on successful clinical outcomes and regulatory approvals.